Javascript must be enabled to continue!
Causes of Hyperprolactinemia in Acromegalic Patients and Clinical Correlations
View through CrossRef
Hyperprolactinemia in acromegalic patients may result either from cosecretion of growth hormone and prolactin by the tumour or from pituitary stalk compression. The occurrence of both conditions is possible. This study was designed aiming 1) to estimate the prevalence of each cause of hyperprolactinemia and its respective clinical course; 2) to compare the outcomes of patients with tumours staining only for growth hormone against tumours staining for both growth hormone and prolactin. 75 acromegalic patients submitted to transsphenoidal surgery between 1989 and 2018 were included. Patients were divided based on preoperative prolactin levels and immunostaining pattern. Statistical analysis was performed with SPSS version 23. Hyperprolactinemia was documented in 22 out of 36 patients (61%). Stalk compression was the only underlying cause of hyperprolactinemia in 45% of cases. The levels of prolactin were not associated with the immunostaining pattern for prolactin. Clinical differences were not observed between hyperprolactinemic and normoprolactinemic patients, except for a higher frequency of cavernous sinus invasion (64% vs 29%, p=0,064), that reached the level of significance for the subgroup with macroadenomas staining exclusively for growth hormone (p=0,031). In the present series, no clinical differences were noticed between patients with tumours staining only for growth hormone or staining for both growth hormone and prolactin. Hyperprolactinemia resulting from stalk compression is likely to anticipate a less favourable course of disease, since it is associated with larger tumours and a higher frequency of cavernous sinus invasion. On the contrary, positive immunostaining for prolactin was not a marker of worse prognosis.
Title: Causes of Hyperprolactinemia in Acromegalic Patients and Clinical Correlations
Description:
Hyperprolactinemia in acromegalic patients may result either from cosecretion of growth hormone and prolactin by the tumour or from pituitary stalk compression.
The occurrence of both conditions is possible.
This study was designed aiming 1) to estimate the prevalence of each cause of hyperprolactinemia and its respective clinical course; 2) to compare the outcomes of patients with tumours staining only for growth hormone against tumours staining for both growth hormone and prolactin.
75 acromegalic patients submitted to transsphenoidal surgery between 1989 and 2018 were included.
Patients were divided based on preoperative prolactin levels and immunostaining pattern.
Statistical analysis was performed with SPSS version 23.
Hyperprolactinemia was documented in 22 out of 36 patients (61%).
Stalk compression was the only underlying cause of hyperprolactinemia in 45% of cases.
The levels of prolactin were not associated with the immunostaining pattern for prolactin.
Clinical differences were not observed between hyperprolactinemic and normoprolactinemic patients, except for a higher frequency of cavernous sinus invasion (64% vs 29%, p=0,064), that reached the level of significance for the subgroup with macroadenomas staining exclusively for growth hormone (p=0,031).
In the present series, no clinical differences were noticed between patients with tumours staining only for growth hormone or staining for both growth hormone and prolactin.
Hyperprolactinemia resulting from stalk compression is likely to anticipate a less favourable course of disease, since it is associated with larger tumours and a higher frequency of cavernous sinus invasion.
On the contrary, positive immunostaining for prolactin was not a marker of worse prognosis.
Related Results
PCOS and Hyperprolactinemia: Conflicting Conditions or Comorbidities?
PCOS and Hyperprolactinemia: Conflicting Conditions or Comorbidities?
Currently, hyperprolactinemia is considered as a condition to be excluded during the diagnosis of polycystic ovarian syndrome (PCOS), because it often demonstrates clinical signs s...
PATTERN OF CLINICAL PRESENTATION OF HYPERPLOLACTINEMIA AMONG INFERTILE PATIENTS
PATTERN OF CLINICAL PRESENTATION OF HYPERPLOLACTINEMIA AMONG INFERTILE PATIENTS
INTRODUCTION– The prevalence of hyperprolactinemia ranges from 0.4% in unselected normal adult females to as
high as 9%–17% in females with reproductive health disorders.The etiolo...
The importance of routine screening for macroprolactin in symptomatic patients with idiopathic hyperprolactinemia
The importance of routine screening for macroprolactin in symptomatic patients with idiopathic hyperprolactinemia
Objective: To evaluate the importance of screening for macroprolactin in symptomatic patients with apparent idiopathic hyperprolactinemia. Methods: During 20 months, the prevalence...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Correlations Developed To Predict Two Phase Flow Through Wellhead Chokes
Correlations Developed To Predict Two Phase Flow Through Wellhead Chokes
Abstract
The predictive accuracy of eight critical two-phase flow correlations aretested against field measured production data, from 210 well tests, coveringbroa...
Cabergoline - Dopamine Receptor Agonist
Cabergoline - Dopamine Receptor Agonist
Background: Cabergoline is a potent dopamine receptor agonist used primarily for the treatment of disorders related to dopamine dysregulation. It acts by stimulating dopamine recep...
Macroprolactinemia: Diagnostic, Clinical, and Pathogenic Significance
Macroprolactinemia: Diagnostic, Clinical, and Pathogenic Significance
Macroprolactinemia is characterized by a large molecular mass of PRL (macroprolactin) as the main molecular form of PRL in sera, the frequent elevation of serum PRL (hyperprolactin...
Every high prolactin level does not require treatment!
Every high prolactin level does not require treatment!
Hyperprolactinemia is a condition of elevated prolactin levels in blood. Pathological hyperprolactinemi presents as oligomenorrhea, amenorrhea, galactorrhea, decreased libido, infe...

